Their argument arrives at a pivotal moment. Volume guarantee, a feedback mode that automatically adjusts oscillatory pressure to keep delivered breath volumes near a clinician-chosen target, has been gaining traction in neonatal and pediatric intensive care. A systematic review of high-frequency oscillatory ventilation with volume guarantee in infants, published in the same journal in 2025, helped fuel enthusiasm for the approach, and editorial commentary has asked whether the neonatal community is ready for volume targeting during oscillation at all. What the new correspondence adds is a caution grounded in bench physics: the number a clinician types into the ventilator does not, by itself, define the mechanical dose the lung actually receives.

The technical heart of the argument rests on how oscillatory ventilators work. In high-frequency oscillatory ventilation, gas movement is driven by a rapidly oscillating diaphragm or piston superimposed on a constant mean airway pressure that holds the lung open. The oscillatory pressure amplitude determines how far gas swings back and forth with each cycle, while the frequency, typically measured in hertz, determines how many of those swings occur each second. Delivered tidal volume emerges from the interaction of these settings with the impedance of the respiratory system, a combination of resistance and compliance that varies dramatically between patients, between endotracheal tube sizes, and over the course of an illness. Two infants with identical target tidal volumes may therefore experience very different pressure swings, very different frequencies, and very different patterns of lung stress and strain.

Bench evidence underpins the correspondence’s central claim. In a study published in Archives of Pediatric Critical Care Medicine in 2026, Lilitwat and colleague Yodchai Vorakunthada systematically varied ventilator settings in a pediatric mechanical test lung and measured the tidal volumes actually delivered during oscillation. Their experiments demonstrated that frequency, pressure amplitude, mean airway pressure, inspiratory-expiratory ratio, and airway resistance all influence the volume of gas that reaches the test lung. In other words, delivered tidal volume is not a fixed consequence of a target setting; it is an emergent result of the entire configuration of the ventilator and the mechanical properties of the circuit and airway. A target achieved at a high frequency with a low amplitude is not mechanically equivalent to the same target achieved at a low frequency with a high amplitude, even though the volume readout looks identical.

This distinction matters because the mechanical dose delivered to the lung is what drives both benefit and injury. In conventional ventilation, decades of research have established that excessive tidal volumes and pressures stretch and stress alveoli, triggering ventilator-induced lung injury. During oscillation, the relationship between volume and injury is subtler, since the breaths are small and the protective effect of the strategy depends on maintaining lung volume with mean airway pressure while avoiding both overdistension and collapse. If clinicians judge the intensity of support, or the risk of injury, by the target tidal volume alone, they may overlook the contributions of amplitude and frequency to the oscillatory pressure swings, or the role of mean airway pressure in shaping end-expiratory lung volume. The correspondence suggests that this incomplete accounting could complicate the interpretation of clinical trials comparing ventilation strategies.

The authors point to prior work showing that oscillators themselves differ substantially in how they deliver volume and pressure. A 2015 in vitro comparison of eight high-frequency oscillatory ventilators, led by David Tingay and colleagues and published in Neonatology, found marked variability in performance characteristics between devices, raising the question of whether all oscillators are, in fact, created equal. A 2017 study in Pediatric Critical Care Medicine by Raymond Wong and colleagues examined volume and pressure delivery during pediatric high-frequency oscillatory ventilation and documented discrepancies between set and delivered values. More recently, a 2021 study in Pediatric Pulmonology by Gonzalo Solís-García and colleagues reported that in preterm infants with respiratory distress syndrome, low target volumes combined with high frequencies could achieve adequate ventilation, reinforcing the idea that frequency and volume interact in determining the adequacy of gas exchange.

Against this backdrop, the correspondence frames a practical recommendation for the research community. Future studies of high-frequency oscillatory ventilation with volume guarantee, the authors argue, should report not only the target tidal volume and the achieved tidal volume, but also the oscillatory frequency, the pressure amplitude, proxies of airway resistance, the size of the endotracheal tube, and the carbon dioxide response of the strategy. This expanded reporting standard would allow readers to reconstruct the actual mechanical conditions of each study and to compare results across devices, patient populations, and institutions. Without such detail, the authors warn, the literature risks accumulating studies whose headline volume targets conceal fundamentally different mechanical exposures, making meta-analyses and clinical guidelines less reliable than they appear.

The recommendation also has implications for bedside practice. Clinicians adjusting a volume guarantee setting on an oscillator typically watch the achieved tidal volume and the resulting carbon dioxide levels, titrating the target to keep blood gases in range. The correspondence does not dispute the value of this workflow, but it emphasizes that the same achieved volume can be reached through different combinations of frequency and amplitude, and that these combinations carry different mechanical implications for the lung. A patient with high airway resistance, for example, whether from a small endotracheal tube, airway secretions, or disease itself, may require different pressure amplitudes to achieve the same volume as a patient with low resistance. Tracking resistance proxies and tube size alongside volume data gives clinicians a fuller sense of why a ventilator is behaving as it is, and when a change in the underlying mechanics, rather than the target, is driving a change in ventilation.

It is worth noting the nature of the publication itself. The piece is a correspondence, a format used for scholarly commentary and interpretation rather than original data collection, and the authors state explicitly that no datasets were generated or analyzed for it. Its contribution is a synthesis of existing bench and clinical evidence, assembled to make a methodological point at a time when volume guarantee during oscillation is moving from bench curiosity toward routine clinical use. The authors acknowledge using a language model solely to assist with organization and language refinement, while retaining full responsibility for the scientific content. Both authors declare no competing interests, and the journal’s records show the manuscript was received in late August 2026, accepted in mid-September, and published on October 1, 2026.

For a field that has spent decades refining how to protect the smallest lungs, the message is deceptively simple: a number is not a dose. As volume guarantee becomes more widespread on oscillatory ventilators, the correspondence urges researchers and clinicians alike to resist the convenience of a single target value and to report and reason about the full set of mechanical variables that shape what the lung actually experiences. The next generation of trials, armed with richer descriptions of frequency, amplitude, resistance, and tube size, will be better positioned to answer the question that matters most to patients and families, namely which combinations of settings deliver the benefits of oscillatory ventilation while minimizing its hidden mechanical costs.

Subject of Research: Mechanical determinants of delivered tidal volume during high-frequency oscillatory ventilation with volume guarantee

Article Title: Target tidal volume incompletely describes mechanical dose during high-frequency oscillatory ventilation

Article References: Ostermaier, E. M., & Lilitwat, W. (2026). Target tidal volume incompletely describes mechanical dose during high-frequency oscillatory ventilation. Pediatric Research. https://doi.org/10.1038/s41390-026-05571-7

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05571-7

Keywords: high-frequency oscillatory ventilation, tidal volume, volume guarantee, mechanical ventilation, neonatal intensive care, pediatric research, ventilator-induced lung injury, pressure amplitude, airway resistance, mean airway pressure, endotracheal tube, bench testing

The numbers behind the syndrome remain sobering. ARDS arises from a variety of insults, including pneumonia, sepsis and trauma, and it damages both the alveolar epithelium that forms the air-blood barrier and the capillary endothelium that lines the lung’s blood vessels. That dual injury causes capillary leak, flooding the lung with protein-rich fluid, and it disrupts one of the body’s most elegant physiological tricks: hypoxic pulmonary vasoconstriction, or HPV. In a healthy lung, when a region is poorly ventilated, the tiny arteries feeding it constrict, diverting blood toward better-aerated territory. In ARDS, this reflex is impaired, so blood continues to perfuse collapsed or fluid-filled lung units. The result is intrapulmonary shunt, where blood passes through the lungs without picking up oxygen, alongside increased dead space ventilation, where air reaches regions with no blood flow to receive its carbon dioxide, and, in many patients, pulmonary hypertension.

Why does this matter so much for the patient as a whole? Because the right ventricle, the thin-walled chamber that pumps blood into the lungs, is exquisitely intolerant of pressure. The normal pulmonary circulation is a low-pressure, low-resistance, highly compliant system. In a 70-kilogram adult at rest it holds roughly 300 milliliters of blood, of which about 120 milliliters sit within the alveolar capillaries, and it can absorb large increases in cardiac output with barely a flicker of pressure rise, thanks to the recruitment of previously unperfused vessels and the distension of larger arteries. Normal pulmonary arterial systolic pressure sits between 15 and 25 millimeters of mercury. When ARDS drives vascular resistance upward, the right ventricle dilates, right atrial pressure climbs, venous return is impeded, and cardiac output falls. Right ventricular dysfunction thus becomes both a consequence of ARDS severity and an amplifier of it, disrupting ventilation-perfusion matching and perpetuating the injury.

The authors pay particular attention to the geometry of blood flow within the lung, a concept classically described by the physiologist John West. Because pulmonary arterial pressure is modest, gravity creates a hydrostatic gradient from the non-dependent, uppermost lung regions down to the dependent, lowermost ones. Where lung height exceeds arterial pressure, capillaries collapse completely and flow ceases, the so-called Zone 1; in Zone 2, capillaries partially collapse and flow is intermittent; only in Zone 3, the dependent lung, are vessels fully perfused. Positive airway pressure, the very tool used to keep ARDS patients alive, raises the pressure inside alveoli and expands these poorly perfused zones, worsening the mismatch between ventilation and perfusion. Fluid loading can mitigate the effect, but it illustrates a fundamental tension at the heart of modern ventilatory care: every breath delivered under pressure is also a hemodynamic event.

Mechanical ventilation itself reshapes the pulmonary circulation in ways that are neither linear nor intuitive. The relationship between lung volume and pulmonary vascular resistance is U-shaped. At low to moderate lung volumes, recruitment of extra-alveolar vessels actually lowers resistance, which is why an appropriately chosen level of positive end-expiratory pressure, PEEP, can recruit collapsed alveoli, improve oxygenation, reduce the hypoxic vasoconstrictive drive, and thereby unload the right ventricle. Push lung volume higher, however, and the intra-alveolar vessels are compressed, resistance climbs, and right ventricular afterload rises with it. Excessive tidal volumes also risk ventilator-induced lung injury through direct mechanical stress on alveoli, and the authors highlight a second, less familiar mechanism: the large cyclic swings in right ventricular stroke volume and pulmonary blood flow produced by each breath may themselves induce overperfusion-related vascular stress.

The clinical footprint of this vascular failure is well characterized. Acute cor pulmonale, defined echocardiographically by right ventricular dilation and paradoxical motion of the interventricular septum, occurs in a substantial share of patients with moderate-to-severe ARDS. Known risk factors include pneumonia as the underlying cause, a driving pressure of 18 millimeters of mercury or higher, a ratio of arterial oxygen to inspired oxygen fraction below 150, and an arterial carbon dioxide tension of 48 millimeters of mercury or more. Elevated pulmonary vascular resistance is independently associated with mortality. As resistance rises and the right ventricle dilates, the shared septum bulges into the left ventricle, limiting its filling through ventricular interdependence, and cardiac output drops further. The authors also describe a striking bedside phenomenon first termed the low tide: during each insufflation, right ventricular stroke volume falls, producing measurable swings in pulmonary arterial and systemic pulse pressure. In ARDS patients, systemic pulse pressure variation is associated with worse outcomes, though the authors caution that such dynamic indices are not specific enough on their own, and that assessing the cardiac output response to a passive leg raise remains the more reliable test of fluid responsiveness.

From this physiology flows a treatment philosophy that departs from the aggressive open-lung strategies of recent years. The optimal ventilatory approach, the authors contend, is the one that minimizes blood gas abnormalities while preserving the pulmonary circulation, promoting recruitment rather than overdistension. Because lung injury in ARDS is profoundly heterogeneous, global compliance measurements can be misleading, so the authors advocate a combination of limited tidal volumes and plateau pressures, minimization of driving pressure, careful titration of PEEP to oxygenation, and avoidance of hypercapnia. They point to emerging bedside tools, including electrical impedance tomography, which maps regional ventilation in real time, and the recruitment-to-inflation ratio, as promising ways to explore at the bedside how a given ventilatory strategy affects the pulmonary circulation and the right ventricle. Combining echocardiography with respiratory mechanics monitoring, they suggest, can verify the delicate balance between protecting the lung and protecting the heart.

For the most severely affected patients, the therapeutic ladder extends further. Prone positioning, turning the patient face-down, improves lung mechanics and aeration, reverses dependent alveolar collapse and small-airway air trapping, and, crucially, preserves pulmonary perfusion in the dorsal lung regions, reducing vascular resistance and improving hemodynamics. When prone positioning fails to achieve adequate gas exchange, veno-venous extracorporeal membrane oxygenation can take over part of the gas exchange burden, and it does something remarkable to the circulation as well: by improving oxygenation and reducing the pressure the right ventricle must generate, it lowers pulmonary artery pressure, unloads the right ventricle and increases cardiac output. These interventions, the authors argue, succeed in part precisely because they rescue the pulmonary circulation, not just the lung parenchyma.

The broader message is a call for intellectual realignment in the intensive care unit. Sixty years after Ashbaugh’s landmark description of the syndrome, the authors write that understanding has shifted from a purely respiratory disorder to a dual pathology involving both lung tissue and lung vasculature. An integrated strategy that optimizes oxygenation and ventilation through lung recruitment while minimizing hemodynamic compromise may be more appropriate than traditional open-lung approaches, which risk trading acceptable blood gases for a failing right heart. There are honest gaps in the framework, and the authors acknowledge them: no threshold level of PEEP guarantees hemodynamic safety, because the impact of raising PEEP depends on whether the lung recruits or simply overdistends, and estimates of pulmonary vascular resistance can be obscured by Zone 2 conditions within the injured lung. Even so, the direction of travel is clear. By preserving pulmonary vascular function, clinicians may be able to optimize gas exchange and support cardiac function simultaneously, treating ARDS not as a lung disease with circulatory side effects, but as what it has been all along: a disease of the heart-lung unit.

For a condition that has resisted six decades of therapeutic advances, the reframing carries real weight. It suggests that some of the mortality attributed to refractory hypoxemia may in fact be hemodynamic failure in disguise, visible only to the clinician who thinks to look at the right ventricle and the vessels feeding it. It also offers a unifying explanation for why protective ventilation, prone positioning and extracorporeal support all improve survival: each, in its own way, protects the pulmonary circulation. As monitoring technology brings echocardiography, impedance tomography and respiratory mechanics together at the bedside, the vision of a truly heart-lung-centered approach to ARDS is moving from physiology textbook to daily practice, and that shift may prove to be one of the most consequential ideas in critical care this decade.

Subject of Research: Pulmonary vascular dysfunction and right ventricular failure in acute respiratory distress syndrome

Article Title: The pulmonary circulation in ARDS: from pathophysiology to clinical applications

Article References: Vieillard-Baron, A., Chew, M., & Pinsky, M. R. (2026). The pulmonary circulation in ARDS: from pathophysiology to clinical applications. Intensive Care Medicine. https://doi.org/10.1007/s00134-026-08597-x

Image Credits: AI Generated

DOI: 10.1007/s00134-026-08597-x

Keywords: ARDS, pulmonary circulation, right ventricular dysfunction, pulmonary hypertension, mechanical ventilation, PEEP, acute cor pulmonale, hypoxic pulmonary vasoconstriction, prone positioning, ECMO, ventilator-induced lung injury, hemodynamics

The review’s central reframing is subtle but consequential. Historically, adjuvant therapies were held back as rescue strategies, deployed only when refractory hypoxemia left clinicians with no other options. Current guidelines, by contrast, recommend applying them earlier in the disease course, reflecting the importance of minimizing stress and strain on the injured lung and potentially modulating the immune dysregulation that drives the syndrome. The authors organize commonly used adjuvants not by fashion or habit, but by the relative certainty of their utility and the frequency of their use—a taxonomy that reveals an uncomfortable truth: how often a therapy is used does not always match how well the evidence supports it.

At the top of the evidence hierarchy sits prone positioning, one of the most effective non-pharmacologic strategies for reducing mortality in moderate-to-severe ARDS. Its benefits extend well beyond improved oxygenation. Turning a patient face-down redistributes transpulmonary pressures more homogeneously across the lung, reduces overdistension of dorsal regions, recruits collapsed dependent lung tissue, and mitigates ventilator-induced lung injury. The PROSEVA trial demonstrated a substantial mortality reduction when prone positioning was applied early and for prolonged sessions in severe ARDS, and subsequent meta-analyses confirmed the benefit was greatest when it was combined with low-tidal-volume ventilation and sustained for more than sixteen hours per session. Despite this strong evidence and guideline endorsement, real-world adoption remains inconsistent, hampered by logistical demands and variability in clinician familiarity—a gap the authors describe as both common and serious.

Continuous neuromuscular blockade occupies a more contested middle ground. The physiological rationale is compelling: paralytic agents halt patient–ventilator dyssynchrony, eliminate excessively forceful spontaneous breathing efforts that can themselves injure the lung, control transpulmonary pressures, and reduce oxygen consumption. The ACURASYS trial showed improved survival and less barotrauma with a 48-hour course of early neuromuscular blockade in patients with moderate-to-severe but persistent ARDS. But the later ROSE trial, which applied the drugs slightly earlier in the disease course, found no mortality benefit. The discrepancy may reflect evolving practice—ROSE was conducted amid lighter sedation and higher PEEP, which may have blunted the incremental value of paralysis—or the fact that ACURASYS enrolled patients slightly later, enriching the study population for persistent, harder-to-treat disease. Current guidance favors short-course, targeted use, balanced against the risks of diaphragmatic inactivity and ICU-acquired weakness.

Conservative fluid management tells a different kind of story: modest evidence, near-universal adoption. Pulmonary edema worsens hypoxemia, decreases lung compliance, and amplifies ventilator-induced injury, so draining excess fluid with diuretics—or occasionally renal replacement therapy—directly supports the goals of lung-protective ventilation. The FACTT trial found that a conservative fluid strategy improved oxygenation, shortened the duration of mechanical ventilation, and reduced ICU length of stay, though it produced no mortality benefit. Even without a survival signal, the approach has become standard supportive care, fitting neatly into a broader philosophy of de-resuscitation: meticulous fluid stewardship for critically ill patients who have already received aggressive resuscitation, regardless of whether they carry an ARDS diagnosis.

Corticosteroids, meanwhile, have ridden decades of enthusiasm and disappointment. By attenuating the inflammatory cascade underlying ARDS, steroids promise reduced alveolar inflammation and less fibroproliferation. Recent trials and meta-analyses suggest early corticosteroids may shorten mechanical ventilation and ICU stays, particularly when initiated early in moderate-to-severe disease, and the COVID-19 pandemic cemented dexamethasone as standard care for severe hypoxemic viral pneumonia. Yet uncertainty persists over optimal dosing, duration, and applicability across etiologies. In late-phase ARDS, the evidence is mixed at best: an early trial of prolonged methylprednisolone in unresolving disease was followed by a larger study that failed to replicate a mortality benefit and raised a late mortality signal when treatment began more than fourteen days after ARDS onset. The authors conclude that steroids are best considered a phenotype-dependent therapy rather than a universally effective one, with trial heterogeneity likely reflecting biological differences among patients rather than absent efficacy.

Then there are the therapies that persist despite thin evidence. Inhaled pulmonary vasodilators—nitric oxide and epoprostenol—offer an elegant physiological fix for severe hypoxemia, selectively directing blood flow toward better-ventilated alveoli and reducing pulmonary vascular resistance. Studies consistently show transient oxygenation improvements, but none has demonstrated a mortality benefit, and harms such as renal dysfunction are documented. Guidelines do not recommend routine use. Nevertheless, inhaled vasodilators remain widely employed as short-term bridges to prone positioning, transfer, or escalation to extracorporeal support, and they may ease right ventricular afterload in acute cor pulmonale, though that indication has never been tested in randomized trials. Their persistence, the authors note, embodies the recurring tension between immediate physiological rescue and outcome-based evidence.

The deeper message of the review is that the right question is no longer whether an adjuvant works, but which therapy should be applied, in which patient, at what stage of disease, and to achieve which physiological objective. Timing matters as much as selection: prone positioning early and for long sessions in severe disease, neuromuscular blockade selectively when dyssynchrony and injurious breathing efforts dominate, fluids tightened once resuscitation is complete, steroids matched to inflammatory phenotype and etiology. The authors propose a framework mapping each adjuvant onto the evolving phases of ARDS, treating the syndrome as a moving target rather than a static diagnosis. Static classification at the bedside, they suggest, may ultimately matter less than dynamic reassessment throughout the illness.

Looking forward, the future of adjuvant therapy may be defined less by discovering new drugs than by deploying existing ones better. Advances in phenotyping—biological, physiological, and imaging-based—could identify which patients benefit from which interventions. The hyperinflammatory and hypoinflammatory subphenotypes described by Calfee and colleagues have already shown differential responses to several therapies, suggesting treatment effect varies with host biology rather than the syndrome label alone. Physiological phenotyping—respiratory mechanics, recruitability, respiratory drive, right ventricular function—may sharpen selection further. Equally important, the authors argue, is a willingness to de-adopt therapies lacking a strong evidence base. Adjuvants, they conclude, should not be regarded as rescue therapies of last resort but as targeted tools applied thoughtfully within a broader lung-protective strategy. The goal is deceptively simple to state and hard to achieve: the right adjuvant, for the right patient, at the right time.

Subject of Research: Adjuvant therapies for acute respiratory distress syndrome across the course of the disease

Article Title: Beyond the ventilator: deploying adjuvant therapies across the course of ARDS

Article References: Munshi, L., Rubenfeld, G., & Wunsch, H. (2026). Beyond the ventilator: deploying adjuvant therapies across the course of ARDS. Intensive Care Medicine, 52(9), 2026-2030. https://doi.org/10.1007/s00134-026-08594-0

Image Credits: AI Generated

DOI: 10.1007/s00134-026-08594-0

Keywords: ARDS, mechanical ventilation, prone positioning, neuromuscular blockade, corticosteroids, conservative fluid management, inhaled pulmonary vasodilators, lung-protective ventilation, phenotyping, critical care, ventilator-induced lung injury, intensive care medicine